As compared with the originally believe population of patients with hemophilia, the global population is three times greater, as per a study which will soon be published in the Annals of Internal Medicine Tuesday.
Registry data of the patients was used by a team of worldwide researchers, headed by McMaster University, from Canada, Australia, France, New Zealand, Italy, and the UK. These countries have the most all-inclusive registries of hemophilia. The main reason behind Hemophilia A is a defect in the F8 gene, and the main cause of hemophilia B is a defect in the F9 gene; most men are affected by both types.
According to the meta-analysis, over 1,125,000 men worldwide are suffering from an inherited bleeding disorder. Out of that number, 418,000 have a severe version of the highly undiagnosed disease. Prior to this meta-analysis, nearly 400 thousand people across the globe were estimated to have the disorder.
For the first time ever, the prevalence of the hemophilia was calculated by the study amongst infants at birth. It was found by the researchers that the life expectancy of those with hemophilia is considerably less than others, especially in countries where it is low-income or where is not enough availability of proper treatment. Due to the lack of treatment, chronic, as well as, disabling joint disease is caused whereas brain hemorrhages and bleeding into organs can result in disability and death. Clotting factor replacement therapy is the standard treatment for hemophilia, however, in countries which have constrained health resources, there might be unavailability of it. Severe hemophilia often leads to a considerable economic, as well as, psychological burden on caregivers, patients and the healthcare system as a whole.
For those who are born with hemophilia, the probability of living a life of normal quality and standard duration will be decreased by 77 percent in middle income, 64 percent in upper-middle-income countries, and up to 93 percent in low-income countries.